Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Study of HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia
Complete Title: A Phase Ib Study of the Pharmacokinetics, Safety And Efficacy of Orally Administered HQP1351 in Subjects with Refractory Chronic Myeloid Leukemia (CML) AND PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL)
Trial Phase: I
Investigator: Vivian Oehler
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML CP and AP, who have experienced resistance or intolerance to at least two tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, dasatinib, bosutinib or ponatinib.
Keywords:
- Leukemia, Chronic Myeloid (CML)
- Leukemia, Myeloid
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I
Vivian Oehler
RG1006553
NCT04260022
A Phase Ib Study of the Pharmacokinetics, Safety And Efficacy of Orally Administered HQP1351 in Subjects with Refractory Chronic Myeloid Leukemia (CML) AND PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL)
Leukemia, Chronic Myeloid (CML)
Leukemia, Myeloid